{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T19:49:50Z","timestamp":1760644190273,"version":"3.37.3"},"reference-count":90,"publisher":"Bentham Science Publishers Ltd.","issue":"22","funder":[{"DOI":"10.13039\/501100001807","name":"FAPESP, Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["2018\/22817-2","2019\/11193-0","2021\/11189-3","2022\/01239-6","2022\/02484-4"],"award-info":[{"award-number":["2018\/22817-2","2019\/11193-0","2021\/11189-3","2022\/01239-6","2022\/02484-4"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior - Brasil","doi-asserted-by":"publisher","award":["001"],"award-info":[{"award-number":["001"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The development of clinically viable metformin analogs is a challenge largely to be overcome. Despite being an extremely efficient drug for the treatment of type 2 diabetes mellitus, multiple studies were conducted seeking to improve its hypoglycemic activity or to ameliorate aspects such as the low oral absorption and the incidence of gastrointestinal side effects. Furthermore, efforts have been made to attribute new activities, or even to expand the pre-existing ones, that could enhance its effects in the diabetes, such as pancreas-protective, antioxidant, and anti-inflammatory activities. In this manuscript, we describe the analogs of metformin developed in the last three decades, highlighting the lack of computationally based rational approaches to guide their development. We also discuss this is probably a consequence of how unclear the mechanism of action of the parent drug is and highlight the recent advances towards establishment of the main molecular target(s) for metformin. We also explored the binding of metformin, buformin and phenformin to the mitochondrial respiratory chain complex I through molecular docking analyses and reviewed the prospects of applying computational tools to improve the success in the development of such analogs. Therefore, it becomes evident the wide range of molecular targets, as well as the multiple activities displayed by metformin, make this drug a promising prototype for the development of novel entities, particularly for the treatment of type 2 diabetes mellitus.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867329666220820151959","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T04:38:00Z","timestamp":1661229480000},"page":"2542-2561","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Entering the Sugar Rush Era: Revisiting the Antihyperglycemic\nActivities of Biguanides after a Century of Metformin Discovery"],"prefix":"10.2174","volume":"30","author":[{"given":"Xisto Antonio","family":"de Oliveira Neto","sequence":"first","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of Campinas - UNICAMP, 13083-871 Campinas-SP,\nBrazil"},{"name":"Institute of Chemistry, University of Campinas - UNICAMP, 13083-970 Campinas-SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Barssotti","sequence":"additional","affiliation":[{"name":"Obesity and Comorbidities Research Center, Institute of Biology, University of Campinas-UNICAMP, 13083-864 Campinas-SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Thereza","family":"Fiori-Duarte","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of Campinas - UNICAMP, 13083-871 Campinas-SP,\nBrazil"},{"name":"Institute of Chemistry, University of Campinas - UNICAMP, 13083-970 Campinas-SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena Cristina","family":"de Lima Barbosa","sequence":"additional","affiliation":[{"name":"Obesity and Comorbidities Research Center, Institute of Biology, University of Campinas-UNICAMP,\n13083-864 Campinas-SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel F\u00e1bio","family":"Kawano","sequence":"additional","affiliation":[{"name":"Faculty of Pharmaceutical Sciences, University of Campinas - UNICAMP, 13083-871 Campinas-SP,\nBrazil"},{"name":"Institute of Chemistry, University of Campinas - UNICAMP, 13083-970 Campinas-SP, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1039\/CT9222101790","volume":"121","author":"Werner E.A.","year":"1922","unstructured":"Werner E.A.; Bell J.; The preparation of methylguanidine, and of \u03b2-dimethylguanidine by the interaction of dicyandiamide, and methylammonium and dimethylammonium chlorides respectively. J Chem Soc Trans 1922,121(0),1790-1794","journal-title":"J Chem Soc Trans"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/978-3-662-09127-2_10","author":"Prugnard E.","year":"1996","unstructured":"Prugnard E.; Noel M.; Chemistry and structure-activity relationships of biguanides. Oral Antidiabetics 1996,263-285","journal-title":"Oral Antidiabetics"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/0470015535","author":"Sneader W.","year":"2005","unstructured":"Sneader W.;  Drug discovery: A history 2005,269-286","journal-title":"Drug discovery: A history"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1007\/s00125-017-4318-z","volume":"60","author":"Bailey C.J.","year":"2017","unstructured":"Bailey C.J.; Metformin: Historical overview. Diabetologia 2017,60(9),1566-1576","journal-title":"Diabetologia"},{"year":"1998","key":"ref=5","unstructured":"U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Aproval package for Glucophage tablets, application number 020357, S010. Available from:  (Accessed on: Feb 17, 2022).1998"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"41","author":"Davies M.J.","year":"2018","unstructured":"Davies M.J.; D\u2019Alessio D.A.; Fradkin J.; Kernan W.N.; Mathieu C.; Mingrone G.; Rossing P.; Tsapas A.; Wexler D.J.; Buse J.B.; Management of hyperglycemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2018,41(12),2669-2701","journal-title":"Diabetes Care"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.diabres.2005.02.011","volume":"70","author":"Belcher G.","year":"2005","unstructured":"Belcher G.; Lambert C.; Edwards G.; Urquhart R.; Matthews D.R.; Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res Clin Pract 2005,70(1),53-62","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-09-1186","volume":"9","author":"Ben Sahra I.","year":"2010","unstructured":"Ben Sahra I.; Le Marchand-Brustel Y.; Tanti J-F.; Bost F.; Metformin in cancer therapy: A new perspective for an old antidiabetic drug? Mol Cancer Ther 2010,9(5),1092-1099","journal-title":"Mol Cancer Ther"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"7615","DOI":"10.1021\/jm050602z","volume":"48","author":"Bharatam P.V.","year":"2005","unstructured":"Bharatam P.V.; Patel D.S.; Iqbal P.; Pharmacophoric features of biguanide derivatives: An electronic and structural analysis. J Med Chem 2005,48(24),7615-7622","journal-title":"J Med Chem"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1365-2125.2000.00264.x","volume":"50","author":"Marathe P.H.","year":"2000","unstructured":"Marathe P.H.; Wen Y.; Norton J.; Greene D.S.; Barbhaiya R.H.; Wilding I.R.; Effect of altered gastric emptying and gastrointestinal motility on metformin absorption. Br J Clin Pharmacol 2000,50(4),325-332","journal-title":"Br J Clin Pharmacol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1124\/dmd.107.015495","volume":"35","author":"Zhou M.","year":"2007","unstructured":"Zhou M.; Xia L.; Wang J.; Metformin transport by a newly cloned protonstimulated organic cation transporter (plasma membrane monoamine transporter) expressed in human intestine. Drug Metab Dispos 2007,35(10),1956-1962","journal-title":"Drug Metab Dispos"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.cmet.2015.01.003","volume":"21","author":"He L.","year":"2015","unstructured":"He L.; Wondisford F.E.; Metformin action: Concentrations matter. Cell Metab 2015,21(2),159-162","journal-title":"Cell Metab"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1124\/jpet.102.034140","volume":"302","author":"Wang D.S.","year":"2002","unstructured":"Wang D.S.; Jonker J.W.; Kato Y.; Kusuhara H.; Schinkel A.H.; Sugiyama Y.; Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002,302(2),510-515","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2337\/db14-1388","volume":"64","author":"Dujic T.","year":"2015","unstructured":"Dujic T.; Zhou K.; Donnelly L.A.; Tavendale R.; Palmer C.N.A.; Pearson E.R.; Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: A GoDARTS study. Diabetes 2015,64(5),1786-1793","journal-title":"Diabetes"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3109\/00498259409043220","volume":"24","author":"Wilcock C.","year":"1994","unstructured":"Wilcock C.; Bailey C.J.; Accumulation of metformin by tissues of the normal and diabetic mouse. Xenobiotica 1994,24(1),49-57","journal-title":"Xenobiotica"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s00125-015-3844-9","volume":"59","author":"McCreight L.J.","year":"2016","unstructured":"McCreight L.J.; Bailey C.J.; Pearson E.R.; Metformin and the gastrointestinal tract. Diabetologia 2016,59(3),426-435","journal-title":"Diabetologia"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.2337\/diabetes.49.12.2063","volume":"49","author":"Hundal R.S.","year":"2000","unstructured":"Hundal R.S.; Krssak M.; Dufour S.; Laurent D.; Lebon V.; Chandramouli V.; Inzucchi S.E.; Schumann W.C.; Petersen K.F.; Landau B.R.; Shulman G.I.; Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000,49(12),2063-2069","journal-title":"Diabetes"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0773.1955.tb02972.x","volume":"11","author":"Hollunger G.","year":"1955","unstructured":"Hollunger G.; Guanidines and oxidative phosphorylations. Acta Pharmacol Toxicol (Copenh) 1955,11(Suppl. 1),1-84","journal-title":"Acta Pharmacol Toxicol (Copenh)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/0005-2728(69)90077-2","volume":"172","author":"Sch\u00e4fer G.","year":"1969","unstructured":"Sch\u00e4fer G.; Site-specific uncoupling and inhibition of oxidative phosphorylation by biguanides. II. Biochim Biophys Acta 1969,172(2),334-337","journal-title":"Biochim Biophys Acta"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1042\/bj3480607","volume":"348","author":"Owen M.R.","year":"2000","unstructured":"Owen M.R.; Doran E.; Halestrap A.P.; Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000,348(Pt 3),607-614","journal-title":"Biochem J"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1074\/jbc.275.1.223","volume":"275","author":"El-Mir M.Y.","year":"2000","unstructured":"El-Mir M.Y.; Nogueira V.; Fontaine E.; Av\u00e9ret N.; Rigoulet M.; Leverve X.; Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 2000,275(1),223-228","journal-title":"J Biol Chem"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1042\/BJ20140620","volume":"462","author":"Bridges H.R.","year":"2014","unstructured":"Bridges H.R.; Jones A.J.Y.; Pollak M.N.; Hirst J.; Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 2014,462(3),475-487","journal-title":"Biochem J"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.celrep.2019.09.070","volume":"29","author":"Wang Y.","year":"2019","unstructured":"Wang Y.; An H.; Liu T.; Qin C.; Sesaki H.; Guo S.; Radovick S.; Hussain M.; Maheshwari A.; Wondisford F.E.; O\u2019Rourke B.; He L.; Metformin improves mitochondrial respiratory activity through activation of AMPK. Cell Rep 2019,29(6),1511-1523.e5","journal-title":"Cell Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3389\/fendo.2019.00294","volume":"10","author":"Vial G.","year":"2019","unstructured":"Vial G.; Detaille D.; Guigas B.; Role of mitochondria in the mechanism(s) of action of metformin. Front Endocrinol (Lausanne) 2019,10,294","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1210\/endrev\/bnaa023","volume":"42","author":"LaMoia T.E.","year":"2021","unstructured":"LaMoia T.E.; Shulman G.I.; Cellular and molecular mechanisms of metformin action. Endocr Rev 2021,42(1),77-96","journal-title":"Endocr Rev"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3389\/fendo.2018.00753","volume":"9","author":"Fontaine E.","year":"2018","unstructured":"Fontaine E.; Metformin-induced mitochondrial complex I inhibition: Facts, uncertainties, and consequences. Front Endocrinol (Lausanne) 2018,9,753","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrendo.2013.256","volume":"10","author":"Pernicova I.","year":"2014","unstructured":"Pernicova I.; Korbonits M.; Metformin-mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol 2014,10(3),143-156","journal-title":"Nat Rev Endocrinol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"106114","DOI":"10.1016\/j.phrs.2022.106114","volume":"177","author":"Feng J.","year":"2022","unstructured":"Feng J.; Wang X.; Ye X.; Ares I.; Lopez-Torres B.; Mart\u00ednez M.; Mart\u00ednez-Larra\u00f1aga M-R.; Wang X.; Anad\u00f3n A.; Mart\u00ednez M-A.; Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications. Pharmacol Res 2022,177,106114","journal-title":"Pharmacol Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.2967\/jnumed.116.177774","volume":"57","author":"Gormsen L.C.","year":"2016","unstructured":"Gormsen L.C.; Sundelin E.I.; Jensen J.B.; Vendelbo M.H.; Jakobsen S.; Munk O.L.; Hougaard Christensen M.M.; Br\u00f8sen K.; Fr\u00f8ki\u00e6r J.; Jessen N.; In vivo imaging of human 11C-metformin in peripheral organs: Dosimetry, biodistribution, and kinetic analyses. J Nucl Med 2016,57(12),1920-1926","journal-title":"J Nucl Med"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.tips.2020.09.001","volume":"41","author":"He L.","year":"2020","unstructured":"He L.; Metformin and systemic metabolism. Trends Pharmacol Sci 2020,41(11),868-881","journal-title":"Trends Pharmacol Sci"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1158\/1535-7163.MCT-15-1021","volume":"15","author":"Boukalova S.","year":"2016","unstructured":"Boukalova S.; Stursa J.; Werner L.; Ezrova Z.; Cerny J.; Bezawork-Geleta A.; Pecinova A.; Dong L.; Drahota Z.; Neuzil J.; Mitochondrial targeting of metformin enhances its activity against pancreatic cancer. Mol Cancer Ther 2016,15(12),2875-2886","journal-title":"Mol Cancer Ther"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3389\/fmolb.2016.00043","volume":"3","author":"Giachin G.","year":"2016","unstructured":"Giachin G.; Bouverot R.; Acajjaoui S.; Pantalone S.; Soler-L\u00f3pez M.; Dynamics of human mitochondrial complex I assembly: Implications for neurodegenerative diseases. Front Mol Biosci 2016,3,43","journal-title":"Front Mol Biosci"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2174\/1875692117666181207121639","volume":"16","author":"Rahman S.","year":"2018","unstructured":"Rahman S.; Ahsan T.; Hossain R.; Ahmed T.; Sajib A.A.; molecular mechanism of metformin associated lactic acidosis (MALA)-an in silico exploration. Curr Pharmacogenom Person Med 2018,16(3),199-209","journal-title":"Curr Pharmacogenom Person Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"Pettersen E.F.","year":"2004","unstructured":"Pettersen E.F.; Goddard T.D.; Huang C.C.; Couch G.S.; Greenblatt D.M.; Meng E.C.; Ferrin T.E.; UCSF Chimera-a visualization system for exploratory research and analysis. J Comput Chem 2004,25(13),1605-1612","journal-title":"J Comput Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.cell.2017.07.050","volume":"170","author":"Guo R.","year":"2017","unstructured":"Guo R.; Zong S.; Wu M.; Gu J.; Yang M.; Architecture of human mitochondrial respiratory megacomplex I2III2IV2. Cell 2017,170(6),1247-1257.e12","journal-title":"Cell"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198510512.001.0001","author":"Blow D.M.","year":"2002","unstructured":"Blow D.M.;  Outline of crystallography for biologists 2002","journal-title":"Outline of crystallography for biologists"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/1471-2105-15-197","volume":"15","author":"Oliveira S.H.P.","year":"2014","unstructured":"Oliveira S.H.P.; Ferraz F.A.N.; Honorato R.V.; Xavier-Neto J.; Sobreira T.J.P.; de Oliveira P.S.L.; KVFinder: Steered identification of protein cavities as a PyMOL plugin. BMC Bioinformatics 2014,15(1),197","journal-title":"BMC Bioinformatics"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1900422","DOI":"10.1002\/ejlt.201900422","volume":"122","author":"Oliveira Neto X.A.","year":"2020","unstructured":"Oliveira Neto X.A.; Alves A.C.S.; Dias R.A.; Rodrigues R.P.; Lancellotti M.; Almeida W.P.; Kawano D.F.; Molecular docking reveals the binding modes of anticancer alkylphospholipids and lysophosphatidylcholine within the catalytic domain of cytidine triphosphate: Phosphocholine cytidyltransferase. Eur J Lipid Sci Technol 2020,122(7),1900422","journal-title":"Eur J Lipid Sci Technol"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1758-2946-2-S1-P50","volume":"2","author":"Stierand K.","year":"2010","unstructured":"Stierand K.; Rarey M.; PoseView-Molecular interaction patterns at a glance. J Cheminform 2010,2(S1),50","journal-title":"J Cheminform"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/1074-5521(95)90050-0","volume":"2","author":"Gehlhaar D.K.","year":"1995","unstructured":"Gehlhaar D.K.; Verkhivker G.M.; Rejto P.A.; Sherman C.J.; Fogel D.B.; Fogel L.J.; Freer S.T.; Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: Conformationally flexible docking by evolutionary programming. Chem Biol 1995,2(5),317-324","journal-title":"Chem Biol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.taap.2008.08.013","volume":"233","author":"Dykens J.A.","year":"2008","unstructured":"Dykens J.A.; Jamieson J.; Marroquin L.; Nadanaciva S.; Billis P.A.; Will Y.; Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008,233(2),203-210","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/apha.12311","volume":"213","author":"Piel S.","year":"2015","unstructured":"Piel S.; Ehinger J.K.; Elm\u00e9r E.; Hansson M.J.; Metformin induces lactate production in peripheral blood mononuclear cells and platelets through specific mitochondrial complex I inhibition. Acta Physiol (Oxf) 2015,213(1),171-180","journal-title":"Acta Physiol (Oxf)"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/bcr-2013-008855","volume":"2013","author":"Plumb B.","year":"2013","unstructured":"Plumb B.; Parker A.; Wong P.; Feeling blue with metformin-associated lactic acidosis. BMJ Case Rep 2013,2013(1),2-5","journal-title":"BMJ Case Rep"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/sj.bjp.0707189","volume":"150","author":"Hinke S.A.","year":"2007","unstructured":"Hinke S.A.; Martens G.A.; Cai Y.; Finsi J.; Heimberg H.; Pipeleers D.; Van de Casteele M.; Methyl succinate antagonises biguanide-induced AMPK-activation and death of pancreatic \u03b2-cells through restoration of mitochondrial electron transfer. Br J Pharmacol 2007,150(8),1031-1043","journal-title":"Br J Pharmacol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40635-018-0186-1","volume":"6","author":"Piel S.","year":"2018","unstructured":"Piel S.; Ehinger J.K.; Chamkha I.; Frostner E.\u00c5.; Sj\u00f6vall F.; Elm\u00e9r E.; Hansson M.J.; Bioenergetic bypass using cell-permeable succinate, but not methylene blue, attenuates metformin-induced lactate production. Intensive Care Med Exp 2018,6(1),22","journal-title":"Intensive Care Med Exp"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40635-018-0202-5","volume":"6","author":"Protti A.","year":"2018","unstructured":"Protti A.; Succinate and the shortcut to the cure of metformin-induced lactic acidosis. Intensive Care Med Exp 2018,6(1),35","journal-title":"Intensive Care Med Exp"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nature13270","volume":"510","author":"Madiraju A.K.","year":"2014","unstructured":"Madiraju A.K.; Erion D.M.; Rahimi Y.; Zhang X.M.; Braddock D.T.; Albright R.A.; Prigaro B.J.; Wood J.L.; Bhanot S.; MacDonald M.J.; Jurczak M.J.; Camporez J.P.; Lee H-Y.; Cline G.W.; Samuel V.T.; Kibbey R.G.; Shulman G.I.; Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 2014,510(7506),542-546","journal-title":"Nature"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1074\/jbc.M110.121806","volume":"286","author":"Ouyang J.","year":"2011","unstructured":"Ouyang J.; Parakhia R.A.; Ochs R.S.; Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem 2011,286(1),1-11","journal-title":"J Biol Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1096\/fj.201800529RR","volume":"33","author":"Polianskyte-Prause Z.","year":"2019","unstructured":"Polianskyte-Prause Z.; Tolvanen T.A.; Lindfors S.; Dumont V.; Van M.; Wang H.; Dash S.N.; Berg M.; Naams J.B.; Hautala L.C.; Nisen H.; Mirtti T.; Groop P.H.; W\u00e4h\u00e4l\u00e4 K.; Tienari J.; Lehtonen S.; Metformin increases glucose uptake and acts renoprotectively by reducing SHIP2 activity. FASEB J 2019,33(2),2858-2869","journal-title":"FASEB J"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1172\/JCI13505","volume":"108","author":"Zhou G.","year":"2001","unstructured":"Zhou G.; Myers R.; Li Y.; Chen Y.; Shen X.; Fenyk-Melody J.; Wu M.; Ventre J.; Doebber T.; Fujii N.; Musi N.; Hirshman M.F.; Goodyear L.J.; Moller D.E.; Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001,108(8),1167-1174","journal-title":"J Clin Invest"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1172\/JCI40671","volume":"120","author":"Foretz M.","year":"2010","unstructured":"Foretz M.; H\u00e9brard S.; Leclerc J.; Zarrinpashneh E.; Soty M.; Mithieux G.; Sakamoto K.; Andreelli F.; Viollet B.; Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1\/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010,120(7),2355-2369","journal-title":"J Clin Invest"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1002\/jcp.22410","volume":"226","author":"Lee J.O.","year":"2011","unstructured":"Lee J.O.; Lee S.K.; Jung J.H.; Kim J.H.; You G.Y.; Kim S.J.; Park S.H.; Uhm K-O.; Kim H.S.; Metformin induces Rab4 through AMPK and modulates GLUT4 translocation in skeletal muscle cells. J Cell Physiol 2011,226(4),974-981","journal-title":"J Cell Physiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1038\/nature03967","volume":"437","author":"Koo S.H.","year":"2005","unstructured":"Koo S.H.; Flechner L.; Qi L.; Zhang X.; Screaton R.A.; Jeffries S.; Hedrick S.; Xu W.; Boussouar F.; Brindle P.; Takemori H.; Montminy M.; The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 2005,437(7062),1109-1111","journal-title":"Nature"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cell.2004.09.015","volume":"119","author":"Screaton R.A.","year":"2004","unstructured":"Screaton R.A.; Conkright M.D.; Katoh Y.; Best J.L.; Canettieri G.; Jeffries S.; Guzman E.; Niessen S.; Yates J.R.; Takemori H.; Okamoto M.; Montminy M.; The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell 2004,119(1),61-74","journal-title":"Cell"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nature11808","volume":"494","author":"Miller R.A.","year":"2013","unstructured":"Miller R.A.; Chu Q.; Xie J.; Foretz M.; Viollet B.; Birnbaum M.J.; Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 2013,494(7436),256-260","journal-title":"Nature"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.celrep.2016.04.024","volume":"15","author":"Konopka A.R.","year":"2016","unstructured":"Konopka A.R.; Esponda R.R.; Robinson M.M.; Johnson M.L.; Carter R.E.; Schiavon M.; Cobelli C.; Wondisford F.E.; Lanza I.R.; Nair K.S.; Hyperglucagonemia mitigates the effect of metformin on glucose production in prediabetes. Cell Rep 2016,15(7),1394-1400","journal-title":"Cell Rep"},{"key":"ref=57","author":"Bijarnia-Mahay S.","year":"2019","unstructured":"Bijarnia-Mahay S.; Bhatia S.; Arora V.; Fructose-1,6-bisphosphatase deficiency. GeneReviews 2019","journal-title":"GeneReviews"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41591-018-0159-7","volume":"24","author":"Hunter R.W.","year":"2018","unstructured":"Hunter R.W.; Hughey C.C.; Lantier L.; Sundelin E.I.; Peggie M.; Zeqiraj E.; Sicheri F.; Jessen N.; Wasserman D.H.; Sakamoto K.; Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase. Nat Med 2018,24(9),1395-1406","journal-title":"Nat Med"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41591-018-0125-4","volume":"24","author":"Madiraju A.K.","year":"2018","unstructured":"Madiraju A.K.; Qiu Y.; Perry R.J.; Rahimi Y.; Zhang X-M.; Zhang D.; Camporez J.G.; Cline G.W.; Butrico G.M.; Kemp B.E.; Casals G.; Steinberg G.R.; Vatner D.F.; Petersen K.F.; Shulman G.I.; Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med 2018,24(9),1384-1394","journal-title":"Nat Med"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1074\/jbc.RA118.006670","volume":"294","author":"Alshawi A.","year":"2019","unstructured":"Alshawi A.; Agius L.; Low metformin causes a more oxidized mitochondrial NADH\/NAD redox state in hepatocytes and inhibits gluconeogenesis by a redox-independent mechanism. J Biol Chem 2019,294(8),2839-2853","journal-title":"J Biol Chem"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1021\/jm00129a015","volume":"32","author":"Reitz A.B.","year":"1989","unstructured":"Reitz A.B.; Tuman R.W.; Marchione C.S.; Jordan A.D.; Bowden C.R.; Maryanoff B.E.; Carbohydrate biguanides as potential hypoglycemic agents. J Med Chem 1989,32(9),2110-2116","journal-title":"J Med Chem"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.cbi.2007.11.012","volume":"173","author":"Liu Z.","year":"2008","unstructured":"Liu Z.; Li J.; Zeng Z.; Liu M.; Wang M.; The antidiabetic effects of cysteinyl metformin, a newly synthesized agent, in alloxan- and streptozocin-induced diabetic rats. Chem Biol Interact 2008,173(1),68-75","journal-title":"Chem Biol Interact"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4142","DOI":"10.1021\/jm900274q","volume":"52","author":"Huttunen K.M.","year":"2009","unstructured":"Huttunen K.M.; Mannila A.; Laine K.; Kemppainen E.; Lepp\u00e4nen J.; Veps\u00e4l\u00e4inen J.; J\u00e4rvinen T.; Rautio J.; The first bioreversible prodrug of metformin with improved lipophilicity and enhanced intestinal absorption. J Med Chem 2009,52(14),4142-4148","journal-title":"J Med Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1002\/jps.23221","volume":"101","author":"Huttunen K.M.","year":"2012","unstructured":"Huttunen K.M.; Lepp\u00e4nen J.; Veps\u00e4l\u00e4inen J.; Sirvi\u00f6 J.; Laine K.; Rautio J.; In vitro and in vivo evaluation of a sulfenamide prodrug of basic metformin. J Pharm Sci 2012,101(8),2854-2860","journal-title":"J Pharm Sci"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.1016\/j.bmcl.2014.09.019","volume":"24","author":"Rautio J.","year":"2014","unstructured":"Rautio J.; Vernerov\u00e1 M.; Aufderhaar I.; Huttunen K.M.; Glutathione-S-transferase selective release of metformin from its sulfonamide prodrug. Bioorg Med Chem Lett 2014,24(21),5034-5036","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"103444","DOI":"10.1016\/j.bioorg.2019.103444","volume":"94","author":"Markowicz-Piasecka M.","year":"2020","unstructured":"Markowicz-Piasecka M.; Sikora J.; Zajda A.; Huttunen K.M.; Novel halogenated sulfonamide biguanides with anti-coagulation properties. Bioorg Chem 2020,94,103444","journal-title":"Bioorg Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"28","DOI":"10.15277\/bjd.2020.247","volume":"20","author":"Crabtree T.S.","year":"2020","unstructured":"Crabtree T.S.; DeFronzo R.A.; Ryder R.E.J.; Bailey C.J.; Imeglimin, a novel, first in-class, blood glucose-lowering agent: A systematic review and meta-analysis of clinical evidence. Br J Diabetes 2020,20(1),28-31","journal-title":"Br J Diabetes"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"8768954","DOI":"10.1155\/2020\/8768954","volume":"2020","author":"Yaribeygi H.","year":"2020","unstructured":"Yaribeygi H.; Maleki M.; Sathyapalan T.; Jamialahmadi T.; Sahebkar A.; Molecular mechanisms by which imeglimin improves glucose homeostasis. J Diabetes Res 2020,2020,8768954","journal-title":"J Diabetes Res"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/ddr.21636","volume":"81","author":"Yendapally R.","year":"2020","unstructured":"Yendapally R.; Sikazwe D.; Kim S.S.; Ramsinghani S.; Fraser-Spears R.; Witte A.P.; La-Viola B.; A review of phenformin, metformin, and imeglimin. Drug Dev Res 2020,81(4),390-401","journal-title":"Drug Dev Res"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1080\/14656566.2020.1729123","volume":"21","author":"Johansson K.S.","year":"2020","unstructured":"Johansson K.S.; Br\u00f8nden A.; Knop F.K.; Christensen M.B.; Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. Expert Opin Pharmacother 2020,21(8),871-882","journal-title":"Expert Opin Pharmacother"},{"year":"2022","author":"Poxel S.A.","key":"ref=71","unstructured":"Poxel S.A.; TWYMEEG (Imeglimin) Available from:  (Accessed on: Apr 28, 2022).2022"},{"year":"2012","author":"Cravo D.","key":"ref=72","unstructured":"Cravo D.; Helmreich M.; Separation of triazine derivatives enantiomers using tartaric acid. 2012"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"1000126","DOI":"10.4172\/2155-6156.1000126","volume":"2","author":"Fouqueray P.","year":"2011","unstructured":"Fouqueray P.; Leverve X.; Fontaine E.; Baqui\u00e9 M.; Wollheim C.; Imeglimin-a new oral anti-diabetic that targets the three key defects of type 2 diabetes. J Diabetes Metab 2011,2(4),1000126","journal-title":"J Diabetes Metab"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.2337\/db14-1220","volume":"64","author":"Vial G.","year":"2015","unstructured":"Vial G.; Chauvin M.A.; Bendridi N.; Durand A.; Meugnier E.; Madec A.M.; Bernoud-Hubac N.; Pais de Barros J.P.; Fontaine \u00c9.; Acquaviva C.; Hallakou-Bozec S.; Bolze S.; Vidal H.; Rieusset J.; Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 2015,64(6),2254-2264","journal-title":"Diabetes"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"E461","DOI":"10.1152\/ajpendo.00009.2016","volume":"311","author":"Perry R.J.","year":"2016","unstructured":"Perry R.J.; Cardone R.L.; Petersen M.C.; Zhang D.; Fouqueray P.; Hallakou-Bozec S.; Bolze S.; Shulman G.I.; Petersen K.F.; Kibbey R.G.; Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents. Am J Physiol Endocrinol Metab 2016,311(2),E461-E470","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"15072","DOI":"10.1038\/cddiscovery.2015.72","volume":"2","author":"Detaille D.","year":"2016","unstructured":"Detaille D.; Vial G.; Borel A.L.; Cottet-Rouselle C.; Hallakou-Bozec S.; Bolze S.; Fouqueray P.; Fontaine E.; Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov 2016,2(1),15072","journal-title":"Cell Death Discov"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/j.1463-1326.2012.01611.x","volume":"14","author":"Pirags V.","year":"2012","unstructured":"Pirags V.; Lebovitz H.; Fouqueray P.; Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 2012,14(9),852-858","journal-title":"Diabetes Obes Metab"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/dom.12452","volume":"17","author":"Pacini G.","year":"2015","unstructured":"Pacini G.; Mari A.; Fouqueray P.; Bolze S.; Roden M.; Imeglimin increases glucose-dependent insulin secretion and improves \u03b2-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2015,17(6),541-545","journal-title":"Diabetes Obes Metab"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"565","DOI":"10.2337\/dc12-0453","volume":"36","author":"Fouqueray P.","year":"2013","unstructured":"Fouqueray P.; Pirags V.; Inzucchi S.E.; Bailey C.J.; Schernthaner G.; Diamant M.; Lebovitz H.E.; The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 2013,36(3),565-568","journal-title":"Diabetes Care"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.2337\/dc13-2349","volume":"37","author":"Fouqueray P.","year":"2014","unstructured":"Fouqueray P.; Pirags V.; Diamant M.; Schernthaner G.; Lebovitz H.E.; Inzucchi S.E.; Bailey C.J.; The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care 2014,37(7),1924-1930","journal-title":"Diabetes Care"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1055\/s-0042-107349","volume":"66","author":"Abbas S.Y.","year":"2016","unstructured":"Abbas S.Y.; Basyouni W.M.; El-Bayouki K.A.M.; Abdel-Rahman R.F.; Synthesis and Evaluation of 1-substituted-biguanide derivatives as anti-diabetic agents for type II diabetes insulin resistant. Drug Res (Stuttg) 2016,66(7),377-383","journal-title":"Drug Res (Stuttg)"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1055\/s-0043-102692","volume":"67","author":"Abbas S.Y.","year":"2017","unstructured":"Abbas S.Y.; Basyouni W.M.; El-Bayouk K.A.M.; Tohamy W.M.; Aly H.F.; Arafa A.; Soliman M.S.; New biguanides as anti-diabetic agents part I: Synthesis and evaluation of 1-substituted biguanide derivatives as anti-diabetic agents of type II diabetes insulin resistant. Drug Res (Stuttg) 2017,67(10),557-563","journal-title":"Drug Res (Stuttg)"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1700183","DOI":"10.1002\/ardp.201700183","volume":"350","author":"Basyouni W.M.","year":"2017","unstructured":"Basyouni W.M.; Abbas S.Y.; El Shehry M.F.; El-Bayouki K.A.M.; Aly H.F.; Arafa A.; Soliman M.S.; New biguanides as anti-diabetic agents, part II: Synthesis and anti-diabetic properties evaluation of 1-arylamidebiguanide derivatives as agents of insulin resistant type II diabetes. Arch Pharm (Weinheim) 2017,350(11),1700183","journal-title":"Arch Pharm (Weinheim)"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"239","DOI":"10.22159\/ijpps.2017v9i1.15250","volume":"9","author":"Mahdi M.F.","year":"2016","unstructured":"Mahdi M.F.; Arif I.S.; Jubair N.K.; Design, synthesis and preliminary pharmacological evaluation of new metformin derivatives. Int J Pharm Pharm Sci 2016,9(1),239-245","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1055\/s-0043-106444","volume":"67","author":"Ramya V.","year":"2017","unstructured":"Ramya V.; Vembu S.; Ariharasivakumar G.; Gopalakrishnan M.; Synthesis, characterisation, molecular docking, anti-microbial and anti-diabetic screening of substituted 4-indolylphenyl-6-arylpyrimidine-2-imine Derivatives. Drug Res (Stuttg) 2017,67(9),515-526","journal-title":"Drug Res (Stuttg)"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.3390\/molecules22101752","volume":"22","author":"Cao H.","year":"2017","unstructured":"Cao H.; Liao S.; Zhong W.; Xiao X.; Zhu J.; Li W.; Wu X.; Feng Y.; Synthesis, characterization, and biological evaluations of 1,3,5-triazine derivatives of metformin cyclization with berberine and magnolol in the presence of sodium methylate. Molecules 2017,22(10),1752","journal-title":"Molecules"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.biopha.2018.04.065","volume":"103","author":"Jia D.","year":"2018","unstructured":"Jia D.; Li Z.; Gao Y.; Feng Y.; Li W.; A novel triazine ring compound (MD568) exerts in vivo and in vitro effects on lipid metabolism. Biomed Pharmacother 2018,103,790-799","journal-title":"Biomed Pharmacother"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1111\/1440-1681.13302","volume":"47","author":"Chen D.","year":"2020","unstructured":"Chen D.; Jia D.; Wu X.; Shi K.; Ren C.; Dou Y.; Guo M.; Wang J.; Ma M.; Wu Z.; Shi H-Y.; Li W.; Feng Y.; Wu F.; A novel metformin derivative showed improvement of lipid metabolism in obese rats with type 2 diabetes. Clin Exp Pharmacol Physiol 2020,47(8),1382-1392","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/1440-1681.13085","volume":"46","author":"Jia D.","year":"2019","unstructured":"Jia D.; Li Z.W.; Zhou X.; Gao Y.; Feng Y.; Ma M.; Wu Z.; Li W.; A novel berberine-metformin hybrid compound exerts therapeutic effects on obese type 2 diabetic rats. Clin Exp Pharmacol Physiol 2019,46(6),533-544","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1212609","DOI":"10.1155\/2017\/1212609","volume":"2017","author":"Guti\u00e9rrez-Lara E.","year":"2017","unstructured":"Guti\u00e9rrez-Lara E.; Mart\u00ednez-Conde C.; Rosales-Ortega E.; Ram\u00edrez-Espinosa J.J.; Rivera-Leyva J.C.; Centuri\u00f3n D.; Carvajal K.; Ortega-Cuellar D.; Estrada-Soto S.; Navarrete-V\u00e1zquez G.; Synthesis and in vitro AMPK activation of cycloalkyl\/ alkarylbiguanides with robust in vivo antihyperglycemic action. J Chem 2017,2017,1212609","journal-title":"J Chem"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220820151959","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/207809\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867329666220820151959","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:44:36Z","timestamp":1698659076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/207809\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":90,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867329666220820151959","relation":{},"ISSN":["0929-8673"],"issn-type":[{"type":"print","value":"0929-8673"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-02-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}